ACL4 Antibody

What is ACSL4 and why are antibodies against it important?

ACSL4 (Acyl-CoA synthetase long chain family member 4) is a protein encoded by the ACSL4 gene in humans. This protein is also known by several other names including ACS4, FACL4, LACS4, MRX63, long-chain-fatty-acid--CoA ligase 4, and acyl-CoA synthetase 4. Structurally, ACSL4 is approximately 79.2 kilodaltons in mass and plays a critical role in fatty acid metabolism . The protein has orthologs in multiple species including canine, porcine, monkey, mouse, and rat models, making it relevant for comparative studies across species .

Antibodies against ACSL4 are important research tools that enable scientists to detect, quantify, and localize this protein in various experimental settings. These antibodies facilitate investigations into ACSL4's role in cellular processes, disease mechanisms, and potential therapeutic interventions. They are particularly valuable for studying the protein's expression patterns, interactions with other molecules, and functional alterations in pathological conditions.

What applications are ACSL4 antibodies commonly used for?

ACSL4 antibodies are versatile tools employed in numerous laboratory techniques:

These applications allow researchers to investigate ACSL4 expression levels, subcellular localization, protein-protein interactions, and post-translational modifications . The selection of a specific application depends on the research question, available sample types, and desired outcomes. For instance, Western blotting is commonly employed for semi-quantitative analysis of ACSL4 expression levels, while immunofluorescence provides insights into the protein's spatial distribution within cells.

How do I select the appropriate ACSL4 antibody for my specific research needs?

Selecting the appropriate ACSL4 antibody requires careful consideration of several factors:

• Species reactivity: Ensure the antibody recognizes ACSL4 in your experimental model (human, mouse, rat, etc.). Cross-reactivity information is typically provided by manufacturers .

• Application compatibility: Verify that the antibody has been validated for your intended application (WB, IHC, IF, etc.). Some antibodies work well for certain applications but not others .

• Antibody type: Consider whether a monoclonal or polyclonal antibody better suits your needs:

  • Monoclonal: Higher specificity, lower background, consistent lot-to-lot performance

  • Polyclonal: Multiple epitope recognition, potentially higher sensitivity

• Epitope location: For studying specific domains or isoforms of ACSL4, select antibodies that target relevant epitopes.

• Validation data: Review available validation data including Western blot images, IHC staining patterns, and published literature citations .

• Conjugation status: Determine if you need an unconjugated primary antibody or one conjugated to an enzyme, fluorophore, or other tag based on your detection method.

Always review product-specific validation data, user reviews, and published literature to ensure the selected antibody has demonstrated reliability in settings similar to your experimental conditions.

What are the critical considerations for optimizing Western blot experiments with ACSL4 antibodies?

Optimizing Western blot experiments with ACSL4 antibodies requires attention to several critical parameters:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors to prevent ACSL4 degradation

  • Consider subcellular fractionation techniques if studying membrane-associated ACSL4 pools

  • Optimize protein loading (typically 20-50 μg total protein) based on ACSL4 expression levels

• Electrophoresis conditions:

  • Use 8-10% polyacrylamide gels to effectively resolve the 79.2 kDa ACSL4 protein

  • Include molecular weight markers that span the expected size range

  • Consider gradient gels if analyzing both ACSL4 and interacting proteins of varying sizes

• Transfer parameters:

  • Optimize transfer time and voltage for complete transfer of the relatively large ACSL4 protein

  • Use PVDF membranes for better protein retention and stronger signal

  • Verify transfer efficiency using reversible protein stains

• Blocking and antibody incubation:

  • Test multiple blocking agents (BSA vs. non-fat milk) as some ACSL4 antibodies perform better with specific blockers

  • Determine optimal primary antibody dilution (typically 1:500-1:2000) through titration experiments

  • Optimize incubation temperature and duration (4°C overnight often yields best results)

• Signal detection:

  • Choose enhanced chemiluminescence (ECL) for standard detection or fluorescent secondary antibodies for quantitative analysis

  • Consider signal amplification methods for low-abundance samples

• Controls:

  • Include positive controls (tissue/cells known to express ACSL4)

  • Include negative controls (ACSL4 knockout samples if available)

  • Use loading controls appropriate for your experimental context

These optimizations help ensure specific detection of ACSL4 while minimizing background and non-specific signals, leading to more reliable and reproducible results.

How do I troubleshoot non-specific binding issues with ACSL4 antibodies?

Non-specific binding is a common challenge when working with antibodies. For ACSL4 antibodies, consider these troubleshooting approaches:

• High background or multiple bands:

  • Increase antibody dilution (use 2-5× more dilute solutions)

  • Optimize blocking conditions (try different blockers or increase blocking time)

  • Add 0.05-0.1% Tween-20 to washing buffers and increase wash duration/frequency

  • Pre-absorb antibody with non-specific proteins or tissues

  • Use more stringent washing conditions (higher salt concentration in wash buffers)

• Cross-reactivity with other ACSL family members:

  • ACSL4 shares sequence homology with other ACSL family proteins, potentially causing cross-reactivity

  • Select antibodies raised against unique regions of ACSL4

  • Validate specificity using recombinant ACSL proteins or knockout/knockdown samples

  • Perform peptide competition assays to confirm specificity

• Non-reproducible results between experiments:

  • Standardize sample preparation protocols

  • Use consistent antibody lots when possible

  • Implement positive and negative controls in each experiment

  • Document exact experimental conditions for troubleshooting

• Weak or absent signal:

  • Verify ACSL4 expression in your samples using published data or RT-PCR

  • Test alternative antibody clones targeting different epitopes

  • Increase protein loading or use enrichment techniques

  • Implement signal amplification methods (e.g., biotin-streptavidin systems)

• Unexpected molecular weight bands:

  • Consider post-translational modifications that alter protein mobility

  • Test reducing vs. non-reducing conditions

  • Evaluate sample preparation methods for potential protein degradation

  • Verify antibody specificity with recombinant ACSL4 protein

Systematic evaluation of these factors can help identify and resolve non-specific binding issues, leading to cleaner and more interpretable results.

What controls should I include when using ACSL4 antibodies in immunological assays?

Robust experimental design requires appropriate controls to validate findings and troubleshoot issues. When using ACSL4 antibodies, consider including:

• Positive controls:

  • Cell lines or tissues known to express ACSL4 (e.g., liver, brain, testis)

  • Recombinant ACSL4 protein as a reference standard

  • Overexpression systems (transiently transfected cells)

• Negative controls:

  • ACSL4 knockout or knockdown samples

  • Tissues or cells known not to express ACSL4

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls to evaluate background signal

• Technical controls:

  • Loading controls for Western blots (β-actin, GAPDH, tubulin)

  • Nuclear or cytoplasmic markers for subcellular localization studies

  • Peptide competition assays to confirm antibody specificity

  • Multiple antibody clones targeting different ACSL4 epitopes

• Validation across techniques:

  • Confirm protein expression using orthogonal methods (e.g., mass spectrometry)

  • Correlate protein detection with mRNA expression

  • Use multiple detection methods (e.g., fluorescence and chromogenic detection)

• Quantitative controls:

  • Standard curves using recombinant ACSL4 for quantitative assays

  • Dilution series to establish linear detection range

  • Inter-assay calibrators for longitudinal studies

Including these controls enhances experimental rigor and facilitates interpretation of results, especially when investigating ACSL4 expression or function in novel contexts or when using newly developed antibodies.

How can active learning strategies improve ACSL4 antibody-antigen binding prediction?

Active learning (AL) strategies can significantly enhance the efficiency and accuracy of predicting ACSL4 antibody-antigen binding interactions by strategically selecting the most informative experimental data points. These approaches are particularly valuable when working with limited resources or large antibody libraries:

• Principles of active learning for antibody research:

  • AL employs iterative cycles of prediction, experimental validation, and model updating

  • The approach minimizes experimental efforts by prioritizing the most informative experiments

  • For ACSL4 studies, this reduces the number of costly binding assays needed to characterize antibody specificity and affinity

• Effective AL strategies based on recent research:

  • Hamming Average Distance method: This diversity-based approach selects antibody-antigen pairs based on sequence differences, achieving up to 35% reduction in required experiments

  • Gradient-Based Uncertainty (Last Layer Max): Identifies antigen variants that generate the largest model gradient, indicating areas of prediction uncertainty

  • Query-by-Committee: Employs multiple models to identify antibody-antigen pairs with the highest prediction disagreement, highlighting informative experiments

• Implementation for ACSL4 research:

  • Start with small, strategically selected subsets of ACSL4 antibody-antigen binding data

  • Apply computational models to predict binding across a larger space of potential interactions

  • Identify the most informative next experiments (those that would most improve model accuracy)

  • Iteratively expand the dataset by experimentally testing the selected pairs

  • Update models with new data and repeat the cycle

• Benefits for ACSL4 antibody characterization:

  • Reduces experimental burden by up to 35% compared to random selection approaches

  • Accelerates development timeline (achieving target accuracy 28 steps earlier in testing)

  • Enables more comprehensive mapping of epitope-paratope interactions

  • Facilitates identification of cross-reactive epitopes shared with other ACSL family members

Recent studies using the Absolut! simulation framework demonstrated that these AL strategies significantly outperformed random selection approaches for antibody-antigen binding prediction, making them valuable tools for characterizing ACSL4 antibodies with minimal experimental investment .

What approaches are most effective for validating ACSL4 antibody specificity across species?

Validating ACSL4 antibody specificity across species is critical for comparative studies and preclinical research. Since ACSL4 has orthologs in various species including human, mouse, rat, canine, and porcine models , comprehensive validation strategies include:

• Sequence homology analysis:

  • Align ACSL4 protein sequences across target species to identify conserved and variable regions

  • Predict cross-reactivity based on epitope conservation in target species

  • Select antibodies raised against highly conserved epitopes for multi-species applications

  • Consider species-specific antibodies for regions with low sequence homology

• Stepwise experimental validation:

  • Western blot analysis: Compare band patterns and molecular weights across species samples

  • Immunoprecipitation-Mass Spectrometry: Confirm pulled-down proteins are ACSL4 orthologs

  • Tissue cross-reactivity studies: Test antibody performance in fixed tissue microarrays from multiple species

  • Functional blocking studies: Assess whether the antibody inhibits ACSL4 function consistently across species

• Knockout/knockdown validation:

  • Test antibody specificity in ACSL4 knockout models from different species

  • Use siRNA or CRISPR approaches to create transient knockdowns for validation

  • Compare signal reduction patterns across species following ACSL4 depletion

• Affinity and binding kinetics characterization:

  • Measure dissociation constants (KD) for the antibody against ACSL4 from different species

  • Compare binding kinetics using surface plasmon resonance or bio-layer interferometry

  • Document species-specific differences in affinity that might affect experimental sensitivity

• Epitope mapping strategies:

  • Use peptide arrays to identify the exact binding epitope across species variants

  • Perform competitive binding assays with species-specific peptides

  • Consider structural biology approaches (X-ray crystallography, cryo-EM) for detailed epitope characterization

The most effective validation approach combines computational analysis with experimental verification across multiple techniques, providing confidence in cross-species applications of ACSL4 antibodies.

How do post-translational modifications of ACSL4 affect antibody binding and experimental outcomes?

Post-translational modifications (PTMs) of ACSL4 can significantly impact antibody recognition and experimental results. Understanding these effects is crucial for accurate interpretation of data:

• Common PTMs affecting ACSL4:

  • Phosphorylation: ACSL4 contains multiple potential phosphorylation sites that may regulate its activity and localization

  • Glycosylation: Potential N-linked glycosylation may affect protein mobility and epitope accessibility

  • Ubiquitination: May signal for protein degradation and alter ACSL4 half-life

  • Proteolytic processing: Can generate distinct fragments with different epitope availability

• Impact on antibody binding:

  • PTMs directly within epitope regions can block antibody recognition

  • Modifications distant from the epitope may alter protein conformation, indirectly affecting binding

  • Some antibodies may preferentially recognize specific modified forms of ACSL4

  • PTM-induced changes in protein-protein interactions may mask epitopes in complex samples

• Experimental considerations:

  • Western blotting: PTMs may cause mobility shifts, resulting in bands at unexpected molecular weights

  • Immunoprecipitation: Modifications may enhance or impair antibody-antigen interactions in solution

  • Immunohistochemistry/Immunofluorescence: Fixation methods can affect PTM preservation and epitope accessibility

  • Flow cytometry: Cell permeabilization protocols may differentially extract modified forms of ACSL4

• Strategies for addressing PTM-related challenges:

  • Use antibodies specifically targeting modified forms of ACSL4 when studying PTM-dependent functions

  • Employ phosphatase, glycosidase, or other enzymatic treatments to remove specific modifications

  • Compare results using multiple antibodies targeting different epitopes

  • Include controls treated with PTM-inducing or PTM-inhibiting conditions

  • Consider using mass spectrometry to characterize the PTM landscape in your experimental system

• Phosphorylation-specific considerations:

  • Treatment with phosphatase inhibitors during sample preparation preserves phosphorylated forms

  • Phosphorylation-specific antibodies can be used to detect activated ACSL4 forms

  • Mobility shift assays (Phos-tag gels) can separate phosphorylated from non-phosphorylated ACSL4

Understanding the impact of PTMs on ACSL4 antibody recognition enables more accurate interpretation of experimental results and can provide insights into the protein's functional regulation in different physiological and pathological contexts.

What are the optimal fixation and permeabilization methods for ACSL4 immunostaining?

The choice of fixation and permeabilization methods significantly impacts ACSL4 detection in immunostaining applications. Different protocols preserve distinct aspects of cellular architecture and protein epitopes:

• Fixation methods comparison:

• Permeabilization optimization:

  • For membrane-associated ACSL4: Mild detergents (0.1-0.2% Triton X-100, 5-10 min)

  • For cytosolic ACSL4: Moderate detergents (0.2-0.5% Triton X-100, 10-15 min)

  • Saponin (0.1%): Reversible permeabilization preserving membrane structures

  • Digitonin (10-50 μg/ml): Selective permeabilization of plasma membrane while preserving organelle membranes

• Protocol optimization strategies:

  • Test multiple fixation-permeabilization combinations with your specific antibody

  • Consider dual fixation protocols (e.g., brief PFA followed by methanol) for certain applications

  • Adjust fixation duration based on sample thickness and density

  • Incorporate antigen retrieval steps for archived or heavily fixed samples

  • Test epitope accessibility using antibodies targeting different ACSL4 domains

• Critical considerations for subcellular localization studies:

  • Fixation artifacts can alter apparent ACSL4 distribution

  • Compare live-cell imaging (with fluorescently tagged ACSL4) to fixed cell results

  • Include organelle markers to verify localization patterns

  • Use super-resolution techniques for detailed localization studies

Optimal protocols should be empirically determined for each antibody-sample combination, with systematic comparison of multiple approaches to identify conditions that maximize signal-to-noise ratio and preserve relevant biological information.

How can I quantitatively assess ACSL4 antibody binding characteristics for my experiment?

Quantitative assessment of ACSL4 antibody binding characteristics is essential for experimental optimization and result interpretation. Several approaches can provide valuable insights:

• Affinity and kinetics measurements:

  • Surface Plasmon Resonance (SPR): Determines association/dissociation rates (ka/kd) and equilibrium dissociation constant (KD)

  • Bio-Layer Interferometry (BLI): Alternative optical technique for real-time binding kinetics

  • Isothermal Titration Calorimetry (ITC): Measures thermodynamic parameters of binding

  • Microscale Thermophoresis (MST): Requires minimal sample amounts for KD determination

• Antibody titration experiments:

  • Perform serial dilutions in your experimental system (WB, ELISA, flow cytometry)

  • Plot signal intensity versus antibody concentration

  • Determine optimal concentration (typically in the linear range of the titration curve)

  • Calculate EC50 values to compare different antibodies objectively

• Competition assays:

  • Use known ACSL4 ligands or substrates to assess epitope accessibility

  • Perform antibody competition assays to identify overlapping epitopes

  • Peptide blocking experiments to confirm epitope specificity

  • Cross-competition between different anti-ACSL4 antibodies

• Specificity quantification:

  • Signal-to-noise ratio calculation across different sample types

  • Comparative analysis in ACSL4-expressing versus knockout samples

  • Cross-reactivity assessment with other ACSL family proteins

  • Specificity index calculation using multiple sample types

• Advanced techniques for detailed characterization:

  • Epitope binning: Groups antibodies based on competitive binding to overlapping epitopes

  • Hydrogen-deuterium exchange mass spectrometry: Maps conformational epitopes

  • X-ray crystallography or cryo-EM: Determines precise epitope structure at atomic resolution

  • Phage display epitope mapping: Identifies linear and conformational epitopes

For ACSL4 antibody research, quantitative binding characteristics can be particularly important when:

• Comparing antibodies targeting different epitopes

• Assessing cross-reactivity with other ACSL family members

• Evaluating species cross-reactivity for preclinical studies

• Developing quantitative assays for ACSL4 expression analysis

These approaches enable rational selection of antibodies with optimal characteristics for specific experimental applications and facilitate standardization across studies.

What techniques can improve the detection sensitivity of ACSL4 in low-expression samples?

Detecting ACSL4 in samples with low expression levels requires specialized approaches to enhance sensitivity while maintaining specificity:

• Sample enrichment strategies:

  • Subcellular fractionation: Concentrate membrane fractions where ACSL4 is often localized

  • Immunoprecipitation: Enrich ACSL4 prior to detection by other methods

  • Proximity ligation assay (PLA): Amplify signal through rolling circle amplification

  • Protein concentration methods: TCA precipitation, methanol/chloroform extraction

• Signal amplification techniques:

  • Tyramide signal amplification (TSA): Enzymatic deposition of fluorescent tyramide

  • Poly-HRP detection systems: Multiple HRP molecules per antibody for enhanced sensitivity

  • Biotin-streptavidin amplification: Leverages high-affinity interaction and multiple binding sites

  • Quantum dot conjugation: Brighter and more photostable than conventional fluorophores

• Advanced detection technologies:

  • Digital ELISA (Simoa): Single-molecule array technology for ultrasensitive detection

  • Mass cytometry (CyTOF): Metal-tagged antibodies with high sensitivity and no autofluorescence

  • Nanoparticle-enhanced detection: Gold or magnetic nanoparticles for signal enhancement

  • Multiphoton excitation microscopy: Improved signal-to-noise ratio in thick specimens

• Optimized imaging approaches:

  • Confocal microscopy with spectral unmixing: Separates specific signal from autofluorescence

  • Deconvolution algorithms: Computational enhancement of signal quality

  • Super-resolution techniques: STORM, PALM, or STED for nanoscale detection

  • Long exposure acquisition: Signal accumulation with low-noise cameras

• Molecular techniques to complement protein detection:

  • In situ hybridization: Detect ACSL4 mRNA as a proxy for protein expression

  • Single-cell transcriptomics: Identify cells expressing ACSL4 for targeted protein analysis

  • Proximity-dependent biotinylation: Detect ACSL4 interaction partners

  • CRISPR-mediated tagging: Endogenous tagging for improved detection

• Quantitative considerations:

  • Implement rigorous background subtraction methods

  • Use internal standards for quantification

  • Employ image analysis software for objective signal quantification

  • Consider statistically robust sampling to detect rare positive events

These approaches can be used individually or in combination, depending on the specific research question, sample type, and available resources. Pilot experiments comparing multiple methods may be necessary to identify the optimal approach for a particular experimental system.